Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Zeuspaul who wrote (11787)	11/26/1997 4:37:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

IDPH had some good news today (although stock price fell victim to the all too common "buy on rumor, sell on news" syndrome that has become very prevalent in Biotechs): By Lauran Neergaard The Associated Press W A S H I N G T O N, Nov. 26 - Thousands of patients with an incurable type of non-Hodgkin's lymphoma won their first new weapon in a decade Wednesday. The Food and Drug Administration approved a novel, genetically engineered drug to attack the immune system cancer with far fewer side effects than standard treatment. Rituxan is not a cure, but the FDA said it has an "excellent" success rate in shrinking tumors safely. The approval makes Rituxan the nation's first anti-cancer monoclonal antibody-a long-awaited biotherapy in which specially manufactured antibodies bind to cancer cells and trigger the immune system to do the killing instead of toxic chemicals. One patient who tested Rituxan called the approval "something to celebrate this Thanksgiving." Renewed Hope "Even though my type of lymphoma is still considered incurable, Rituxan has renewed my hope of raising my three children," said Dr. Wendy Harpham, a Richardson, Texas, physician who failed other treatments before Rituxan therapy put her cancer in remission. About 240,000 Americans have non-Hodgkin's lymphoma, a cancer of the lymph system that targets vital white blood cells. Many patients are successfully treated. But about half of them have an incurable form called low-grade non-Hodgkin's that causes repeat relapses over six or seven years. These patients try high doses of chemotherapy, radiation and bone marrow transplants that can cause severe side effects, particularly when these treatments also kill healthy cells that get in the way. Rituxan, on the other hand, is made from a genetically engineered mouse antibody designed to be a more specific treatment. Scientists don't know exactly how it works, said FDA monoclonal antibody chief Kathryn Stein. But ultimately these antibodies zero in on the white blood cells involved in non-Hodgkin's lymphoma and trigger their death. "This is the first of what we hope will be many monoclonal antibodies for tumor treatment," she said. In a study of 166 patients with advanced cancer, 48 percent had their tumors shrink by at least half. Six percent of patients had complete remissions. Half the successful patients remained stable for more than 11 months, a rate that Stein called "excellent." No Need for Hospitals Rituxan therapy does not require hospitalization. Manufacturers IDEC Pharmaceuticals and Genentech Inc. say Rituxan, known chemically as rituximab, will be available within a month. A complete course of four weekly transfusions will cost roughly $9,000, comparable to many chemotherapies. Rituxan has some risks. It can kill healthy white blood cells as well as cancerous ones, meaning patients could suffer infections although no unusual rates have appeared so far, said Dr. Peter McLaughlin of the M.D. Anderson Cancer Center, the drug's lead investigator. Those cells grow back on their own within a year. Additionally, most patients have temporary and mild flu-like symptoms, such as fever and chills, one to two hours after the first infusion, as their bodies learn to recognize the new antibody, he said. So few side effects make Rituxan a prime candidate to give to lymphoma patients in addition to chemotherapy, hoping for a one-two punch against the disease, McLaughlin said. Doctors already are studying how well such a combination could work, as well as the feasibility of giving it to earlier patients instead of waiting until they relapse. But for patients today, Rituxan promises to buy some time. Harpham says if she hadn't gotten to test the drug, she would already have tried her last option-a bone marrow transplant that she still can turn to if she has another relapse. Still, "Rituxan has been the closest answer to my prayers so far," she said.

To: Zeuspaul who wrote (11787)	11/26/1997 4:44:00 PM
From: tonyt	Read Replies (1) \| Respond to of 32384

>...and pretends to be a savior. Well, he was correct in his price prediction. And this pick-up in volume (IMO) is not a good sign. I still believe that LGND will be under $12 soon, and will hit a low of $10 by year end.

To: Zeuspaul who wrote (11787)	11/26/1997 4:58:00 PM
From: Andrew H	Respond to of 32384

>> It ( I use gender neutral as I do not know the sex) has an obsession with annoying the thread. It always plays innocence and pretends to be a savior , rescuing us from the evils of false and misleading posts. It has an answer for everything. It is purely and simply a game<< Well said, ZP. I think you have hit on the proper pronoun for referring to this poster.